Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and m...
Saved in:
Main Authors: | Alberto Esteban-Fernández, Alejandro Recio-Mayoral, Raquel López-Vilella, Gregorio de Lara, Moisés Barrantes-Castillo, Inés Gómez-Otero, Julio Nuñez-Villota, Carolina Robles-Gamboa, José López-Aguilera, Ángel Iniesta-Manjavacas, Paula Fluviá, Francisco Pastor-Pérez, Laia Belarte-Tornero, Gonzalo Alonso-Salinas, Pablo Díez-Villanueva |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01) -
Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01) -
Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
by: Enrique Santas, et al.
Published: (2020-06-01) -
Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature
by: Eric Wierda, et al.
Published: (2020-06-01) -
The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden
by: Elena Revuelta-López, et al.
Published: (2025-01-01)